{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:48:20Z","timestamp":1783547300408,"version":"3.55.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijantimicag.2023.106920","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T12:25:07Z","timestamp":1689078307000},"page":"106920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-7777","authenticated-orcid":false,"given":"Mary E.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-4772","authenticated-orcid":false,"given":"Rachel M.","family":"Belcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Engeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-8400","authenticated-orcid":false,"given":"Eric","family":"Wenzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-911X","authenticated-orcid":false,"given":"Zackery P.","family":"Bulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott T.","family":"Benken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106920_bib0001","unstructured":"Baricitinib [package insert]. https:\/\/uspl.lilly.com\/olumiant\/olumiant.html#pi. Indianapolis, Indiana: Eli Lilly; 2022."},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0002","first-page":"2281","article-title":"Baricitinib is first approved COVID-19 immunomodulatory treatment","volume":"327","author":"Rubin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0004","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19 (COV-BARRIER): a randomized, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/CCM.0000000000005756","article-title":"Outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19","volume":"51","author":"Peterson","year":"2023","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0006","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/ndt\/gfaa231","article-title":"Targeting acute kidney injury in COVID-19","volume":"35","author":"Kellum","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0007","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1159\/000511161","article-title":"Acute kidney injury in COVID-19: another challenge for nephrology","volume":"51","author":"Rudnick","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0008","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1159\/000511160","article-title":"Acute kidney injury in COVID-19 patients: an inner city hospital experience and policy implications","volume":"51","author":"Zahid","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0009","first-page":"727","article-title":"COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality initiative (ADQI) workgroup","volume":"382","author":"Nadim","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13054-015-0920-y","article-title":"Evolution of chronic renal impairment and long-term mortality after de novo acute kidney injury in the critically ill; a Swedish multi-centre cohort study","volume":"19","author":"Rimes-Stigare","year":"2015","journal-title":"Crit Care (London, England)"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0011","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX Randomized Clinical Trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0012","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cpdd.868","article-title":"Pharmacokinetics, safety, and tolerability of a single- and multiple-dose once-daily baricitinib in healthy Chinese subjects: a randomized placebo-controlled study","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0013","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK \u00bd inhibitor, in healthy volunteers","volume":"54","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106920_bib0014","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/cpt.2600","article-title":"Physiologically-based pharmacokinetic modeling to investigate baricitinib and tofacitinib dosing recommendations for COVID-19 in geriatrics","volume":"112","author":"Wang","year":"2022","journal-title":"Clin Pharmacol Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:47:46Z","timestamp":1760377666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0924857923001991"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106920","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106920"}}